TRCT
INSP icon

Tower Research Capital (TRC)’s Inspire Medical Systems INSP Stock Holding History

Tower Research Capital (TRC)’s Portfolio INSP Stock Details INSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.4K Buy
2,228
+1,627
+271% +$77.2K ﹤0.01% 2192
2026
Q1 		$31K Buy
601
+510
+560% +$35.7K ﹤0.01% 3142
2025
Q4 		$8.39K Sell
91
-458
-83% -$43.8K ﹤0.01% 3953
2025
Q3 		$40.7K Buy
549
+397
+261% +$40.2K ﹤0.01% 2698
2025
Q2 		$19.7K Sell
152
-30
-16% -$4.35K ﹤0.01% 3689
2025
Q1 		$29K Sell
182
-1,093
-86% -$198K ﹤0.01% 2644
2024
Q4 		$236K Sell
1,275
-979
-43% -$190K ﹤0.01% 1604
2024
Q3 		$476K Sell
2,254
-2,917
-56% -$507K 0.01% 900
2024
Q2 		$692K Buy
5,171
+1,882
+57% +$356K 0.01% 1059
2024
Q1 		$706K Buy
3,289
+2,619
+391% +$513K 0.02% 675
2023
Q4 		$136K Sell
670
-2,444
-78% -$396K ﹤0.01% 2400
2023
Q3 		$618K Buy
3,114
+2,800
+892% +$706K 0.02% 757
2023
Q2 		$102K Sell
314
-2,833
-90% -$809K ﹤0.01% 2015
2023
Q1 		$737K Buy
3,147
+3,008
+2,164% +$760K 0.02% 609
2022
Q4 		$36K Sell
139
-6,068
-98% -$1.29M ﹤0.01% 2585
2022
Q3 		$1.1M Buy
6,207
+5,077
+449% +$1.02M 0.02% 666
2022
Q2 		$206K Sell
1,130
-824
-42% -$164K ﹤0.01% 1755
2022
Q1 		$501K Buy
1,954
+1,249
+177% +$285K ﹤0.01% 1151
2021
Q4 		$162K Sell
705
-150
-18% -$36.6K ﹤0.01% 1920
2021
Q3 		$199K Sell
855
-552
-39% -$115K 0.01% 1827
2021
Q2 		$272K Sell
1,407
-62
-4% -$12.3K 0.01% 1685
2021
Q1 		$304K Sell
1,469
-851
-37% -$181K 0.01% 1659
2020
Q4 		$436K Sell
2,320
-16,895
-88% -$2.76M 0.01% 1094
2020
Q3 		$2.48M Buy
19,215
+16,084
+514% +$1.77M 0.03% 274
2020
Q2 		$272K Buy
+3,131
New +$241K 0.01% 1535
2020
Q1 		– Sell
-130
Closed -$10K – 3459
2019
Q4 		$10K Buy
+130
New +$8.36K ﹤0.01% 2327
2019
Q2 		– Sell
-3,727
Closed -$212K – 3966
2019
Q1 		$212K Buy
+3,727
New +$201K 0.01% 1112
2018
Q4 		– Sell
-736
Closed -$31K – 4069
2018
Q3 		$31K Buy
+736
New +$34.5K ﹤0.01% 2052

Other funds holding INSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s INSP Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Inspire Medical Systems (INSP) stake by 271% in Q2 2026, buying an estimated $77.2K and bringing the position to 2,228 shares worth $99.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

Tower Research Capital (TRC) first reported a position in INSP in Q3 2018 and has held it in 28 quarters since. The position peaked at $2.48M in Q3 2020. 275 funds tracked by Wall St. Rank hold INSP as of Q2 2026.

  • Tower Research Capital (TRC) held 2,228 shares of Inspire Medical Systems worth $99.4K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,627 Inspire Medical Systems shares in Q2 2026, an estimated $77.2K.
  • Inspire Medical Systems made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2192 holding.
  • Tower Research Capital (TRC) first reported a position in Inspire Medical Systems in Q3 2018 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s Inspire Medical Systems position peaked at $2.48M in Q3 2020.
  • 275 funds tracked by Wall St. Rank held Inspire Medical Systems as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.